Sorafenib and its derivative SC‐49 sensitize hepatocellular carcinoma cells to CS‐1008, a humanized anti‐TNFRSF10B (DR5) antibody
暂无分享,去创建一个
Kuen-Feng Chen | Pei-Jer Chen | A. Cheng | Chun-Yu Liu | C. Shiau | K. Ichikawa | P. Chu | Hui-Ling Chen | W. Tai | Pei‐Jer Chen
[1] Kuen-Feng Chen,et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. , 2011, Journal of hepatology.
[2] Stephen P. H. Alexander,et al. Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.
[3] Kuen-Feng Chen,et al. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. , 2011, European journal of medicinal chemistry.
[4] Kuen-Feng Chen,et al. Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 , 2010, Clinical Cancer Research.
[5] I. Cuthill,et al. Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.
[6] C. Kilkenny,et al. Guidelines for reporting experiments involving animals: the ARRIVE guidelines , 2010, British journal of pharmacology.
[7] Zhao-You Tang,et al. Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.
[8] J. Wiezorek,et al. Death Receptor Agonists as a Targeted Therapy for Cancer , 2010, Clinical Cancer Research.
[9] F. Sinicrope,et al. Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells , 2010, Molecular Cancer Therapeutics.
[10] N. Eritja,et al. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. , 2010, European journal of cancer.
[11] P. Galle,et al. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. , 2009, World journal of gastroenterology.
[12] G. Gores,et al. Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 , 2009, Hepatology.
[13] R. Labianca,et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] H. Hsieh,et al. Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway* , 2009, Journal of Biological Chemistry.
[15] B. Aggarwal,et al. Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1 , 2009, Molecular Pharmacology.
[16] B. Aggarwal,et al. Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1 , 2009, Molecular Cancer Research.
[17] S. Arii,et al. Molecularly targeted therapy for hepatocellular carcinoma , 2009, Cancer science.
[18] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[19] R. Jove,et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas , 2008, Molecular Cancer Therapeutics.
[20] S. Wang,et al. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway , 2008, Oncogene.
[21] Mark J. Smyth,et al. The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.
[22] Kuen-Feng Chen,et al. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. , 2008, Cancer research.
[23] M. Yazawa,et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] J. Posey,et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas , 2008 .
[25] W. El-Deiry,et al. Mcl-1: a gateway to TRAIL sensitization. , 2008, Cancer research.
[26] J A Peters,et al. Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.
[27] David Loegering,et al. MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis , 2007, Journal of Biological Chemistry.
[28] K. Eguchi,et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. , 2007, Journal of hepatology.
[29] D. Germain,et al. Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy , 2007, Clinical Cancer Research.
[30] T. Curran,et al. Deletion of Shp2 in the Brain Leads to Defective Proliferation and Differentiation in Neural Stem Cells and Early Postnatal Lethality , 2007, Molecular and Cellular Biology.
[31] K. Flaherty,et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.
[32] Mark A. Hall,et al. Clearing the TRAIL for Cancer Therapy. , 2007, Cancer cell.
[33] D. Auclair,et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells , 2007, Leukemia.
[34] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[35] Hong Zhang,et al. Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3 , 2006, Clinical Cancer Research.
[36] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[37] M. Gregor,et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAIL , 2006, Hepatology.
[38] H. Yang-Yen. Mcl-1: a highly regulated cell death and survival controller. , 2006, Journal of biomedical science.
[39] E. Rowinsky. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] B. Fang,et al. Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.
[41] G. Gores,et al. Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells , 2004, Cancer Research.
[42] Wafik S El-Deiry,et al. TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.
[43] K. Shiraki,et al. Cellular FLICE/Caspase-8–Inhibitory Protein as a Principal Regulator of Cell Death and Survival in Human Hepatocellular Carcinoma , 2003, Laboratory Investigation.
[44] I. Jeremias,et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.
[45] H. Yang-Yen,et al. Interleukin-3 Stimulation of mcl-1 Gene Transcription Involves Activation of the PU.1 Transcription Factor through a p38 Mitogen-Activated Protein Kinase-Dependent Pathway , 2003, Molecular and Cellular Biology.
[46] A. Martelli,et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation , 2003, Leukemia.
[47] Hoguen Kim,et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin , 2002, Experimental & Molecular Medicine.
[48] S. Fulda,et al. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.
[49] P. Hersey,et al. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.
[50] R. Ho,et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.
[51] J. Passmore,et al. The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen‐specific cytotoxic T‐cell function , 2001, Immunology.
[52] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[53] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[54] Christina Falschlehner,et al. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. , 2009, Advances in experimental medicine and biology.
[55] S. Wilhelm,et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.